Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

338 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K. Shimizu T, et al. Among authors: ohwada s. Cancer Chemother Pharmacol. 2017 Mar;79(3):489-495. doi: 10.1007/s00280-016-3231-3. Epub 2017 Jan 31. Cancer Chemother Pharmacol. 2017. PMID: 28144730 Free PMC article. Clinical Trial.
A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, Ishizuka H. Jansen M, et al. Among authors: ohwada s. Clin Pharmacol Drug Dev. 2018 Aug;7(6):661-669. doi: 10.1002/cpdd.448. Epub 2018 Apr 17. Clin Pharmacol Drug Dev. 2018. PMID: 29663714 Clinical Trial.
338 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page